Selected research
Market Structure
Global Angiotensin Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Angiotensin Receptor Antagonists market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Angiotensin Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Angiotensin Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Angiotensin Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Angiotensin Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Angiotensin Receptor Antagonists include Teva Pharmaceutical, Sanofi, Jhonson and Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Angiotensin Receptor Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Angiotensin Receptor Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Angiotensin Receptor Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Angiotensin Receptor Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.
Angiotensin Receptor Antagonists Segment by Company
Teva Pharmaceutical
Sanofi
Jhonson and Johnson
Novartis
Merck
Eli Lilly
Pfizer
GSK
Bayer
Bristol-Myers Squibb
Astra Zeneca
Angiotensin Receptor Antagonists Segment by Type
Valsartan
Telmisartan
Losartan
Irbesartan
Olmesartan
Azilsartan
Angiotensin Receptor Antagonists Segment by Application
Cardiovascular Diseases
Kidney Diseases
Hypertension
Other
Angiotensin Receptor Antagonists Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiotensin Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Angiotensin Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiotensin Receptor Antagonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Angiotensin Receptor Antagonists market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Angiotensin Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Angiotensin Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Angiotensin Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Valsartan
- Telmisartan
- Losartan
- Irbesartan
- Olmesartan
- Azilsartan
Applications
- Cardiovascular Diseases
- Kidney Diseases
- Hypertension
- Other
Companies covered
- Teva Pharmaceutical
- Sanofi
- Jhonson and Johnson
- Novartis
- Merck
- Eli Lilly
- Pfizer
- GSK
- Bayer
- Bristol-Myers Squibb
- Astra Zeneca
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Angiotensin Receptor Antagonists Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Angiotensin Receptor Antagonists Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Angiotensin Receptor Antagonists Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Angiotensin Receptor Antagonists Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Angiotensin Receptor Antagonists Market Dynamics
- 2.1 Angiotensin Receptor Antagonists Industry Trends
- 2.2 Angiotensin Receptor Antagonists Industry Drivers
- 2.3 Angiotensin Receptor Antagonists Industry Opportunities and Challenges
- 2.4 Angiotensin Receptor Antagonists Industry Restraints
3 Angiotensin Receptor Antagonists Market by Manufacturers
- 3.1 Global Angiotensin Receptor Antagonists Revenue by Manufacturers (2021-2026)
- 3.2 Global Angiotensin Receptor Antagonists Sales by Manufacturers (2021-2026)
- 3.3 Global Angiotensin Receptor Antagonists Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Angiotensin Receptor Antagonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Angiotensin Receptor Antagonists Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Angiotensin Receptor Antagonists Manufacturers, Product Type & Application
- 3.7 Global Angiotensin Receptor Antagonists Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Angiotensin Receptor Antagonists Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Angiotensin Receptor Antagonists Players Market Share by Revenue in 2025
- 3.8.3 2025 Angiotensin Receptor Antagonists Tier 1, Tier 2, and Tier 3
4 Angiotensin Receptor Antagonists Market by Type
- 4.1 Angiotensin Receptor Antagonists Type Introduction
- 4.1.1 Valsartan
- 4.1.2 Telmisartan
- 4.1.3 Losartan
- 4.1.4 Irbesartan
- 4.1.5 Olmesartan
- 4.1.6 Azilsartan
- 4.2 Global Angiotensin Receptor Antagonists Sales by Type
- 4.2.1 Global Angiotensin Receptor Antagonists Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Angiotensin Receptor Antagonists Sales by Type (2021-2032)
- 4.2.3 Global Angiotensin Receptor Antagonists Sales Market Share by Type (2021-2032)
- 4.3 Global Angiotensin Receptor Antagonists Revenue by Type
- 4.3.1 Global Angiotensin Receptor Antagonists Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Angiotensin Receptor Antagonists Revenue by Type (2021-2032)
- 4.3.3 Global Angiotensin Receptor Antagonists Revenue Market Share by Type (2021-2032)
5 Angiotensin Receptor Antagonists Market by Application
- 5.1 Angiotensin Receptor Antagonists Application Introduction
- 5.1.1 Cardiovascular Diseases
- 5.1.2 Kidney Diseases
- 5.1.3 Hypertension
- 5.1.4 Other
- 5.2 Global Angiotensin Receptor Antagonists Sales by Application
- 5.2.1 Global Angiotensin Receptor Antagonists Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Angiotensin Receptor Antagonists Sales by Application (2021-2032)
- 5.2.3 Global Angiotensin Receptor Antagonists Sales Market Share by Application (2021-2032)
- 5.3 Global Angiotensin Receptor Antagonists Revenue by Application
- 5.3.1 Global Angiotensin Receptor Antagonists Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Angiotensin Receptor Antagonists Revenue by Application (2021-2032)
- 5.3.3 Global Angiotensin Receptor Antagonists Revenue Market Share by Application (2021-2032)
6 Global Angiotensin Receptor Antagonists Sales by Region
- 6.1 Global Angiotensin Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Angiotensin Receptor Antagonists Sales by Region (2021-2032)
- 6.2.1 Global Angiotensin Receptor Antagonists Sales by Region (2021-2026)
- 6.2.2 Global Angiotensin Receptor Antagonists Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Angiotensin Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Angiotensin Receptor Antagonists Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Angiotensin Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Angiotensin Receptor Antagonists Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Angiotensin Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Angiotensin Receptor Antagonists Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Angiotensin Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Angiotensin Receptor Antagonists Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Angiotensin Receptor Antagonists Revenue by Region
- 7.1 Global Angiotensin Receptor Antagonists Revenue by Region
- 7.1.1 Global Angiotensin Receptor Antagonists Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Angiotensin Receptor Antagonists Revenue by Region (2021-2026)
- 7.1.3 Global Angiotensin Receptor Antagonists Revenue by Region (2027-2032)
- 7.1.4 Global Angiotensin Receptor Antagonists Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Angiotensin Receptor Antagonists Revenue (2021-2032)
- 7.2.2 North America Angiotensin Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Angiotensin Receptor Antagonists Revenue (2021-2032)
- 7.3.2 Europe Angiotensin Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Angiotensin Receptor Antagonists Revenue (2021-2032)
- 7.4.2 Asia-Pacific Angiotensin Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Angiotensin Receptor Antagonists Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Angiotensin Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Teva Pharmaceutical
- 8.1.1 Teva Pharmaceutical Company Information
- 8.1.2 Teva Pharmaceutical Business Overview
- 8.1.3 Teva Pharmaceutical Angiotensin Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Teva Pharmaceutical Angiotensin Receptor Antagonists Product Portfolio
- 8.1.5 Teva Pharmaceutical Recent Developments
- 8.2 Sanofi
- 8.2.1 Sanofi Company Information
- 8.2.2 Sanofi Business Overview
- 8.2.3 Sanofi Angiotensin Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Sanofi Angiotensin Receptor Antagonists Product Portfolio
- 8.2.5 Sanofi Recent Developments
- 8.3 Jhonson and Johnson
- 8.3.1 Jhonson and Johnson Company Information
- 8.3.2 Jhonson and Johnson Business Overview
- 8.3.3 Jhonson and Johnson Angiotensin Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Jhonson and Johnson Angiotensin Receptor Antagonists Product Portfolio
- 8.3.5 Jhonson and Johnson Recent Developments
- 8.4 Novartis
- 8.4.1 Novartis Company Information
- 8.4.2 Novartis Business Overview
- 8.4.3 Novartis Angiotensin Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Novartis Angiotensin Receptor Antagonists Product Portfolio
- 8.4.5 Novartis Recent Developments
- 8.5 Merck
- 8.5.1 Merck Company Information
- 8.5.2 Merck Business Overview
- 8.5.3 Merck Angiotensin Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Merck Angiotensin Receptor Antagonists Product Portfolio
- 8.5.5 Merck Recent Developments
- 8.6 Eli Lilly
- 8.6.1 Eli Lilly Company Information
- 8.6.2 Eli Lilly Business Overview
- 8.6.3 Eli Lilly Angiotensin Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Eli Lilly Angiotensin Receptor Antagonists Product Portfolio
- 8.6.5 Eli Lilly Recent Developments
- 8.7 Pfizer
- 8.7.1 Pfizer Company Information
- 8.7.2 Pfizer Business Overview
- 8.7.3 Pfizer Angiotensin Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Pfizer Angiotensin Receptor Antagonists Product Portfolio
- 8.7.5 Pfizer Recent Developments
- 8.8 GSK
- 8.8.1 GSK Company Information
- 8.8.2 GSK Business Overview
- 8.8.3 GSK Angiotensin Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 GSK Angiotensin Receptor Antagonists Product Portfolio
- 8.8.5 GSK Recent Developments
- 8.9 Bayer
- 8.9.1 Bayer Company Information
- 8.9.2 Bayer Business Overview
- 8.9.3 Bayer Angiotensin Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Bayer Angiotensin Receptor Antagonists Product Portfolio
- 8.9.5 Bayer Recent Developments
- 8.10 Bristol-Myers Squibb
- 8.10.1 Bristol-Myers Squibb Company Information
- 8.10.2 Bristol-Myers Squibb Business Overview
- 8.10.3 Bristol-Myers Squibb Angiotensin Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Bristol-Myers Squibb Angiotensin Receptor Antagonists Product Portfolio
- 8.10.5 Bristol-Myers Squibb Recent Developments
- 8.11 Astra Zeneca
- 8.11.1 Astra Zeneca Company Information
- 8.11.2 Astra Zeneca Business Overview
- 8.11.3 Astra Zeneca Angiotensin Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Astra Zeneca Angiotensin Receptor Antagonists Product Portfolio
- 8.11.5 Astra Zeneca Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Angiotensin Receptor Antagonists Value Chain Analysis
- 9.1.1 Angiotensin Receptor Antagonists Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Angiotensin Receptor Antagonists Production Mode & Process
- 9.2 Angiotensin Receptor Antagonists Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Angiotensin Receptor Antagonists Distributors
- 9.2.3 Angiotensin Receptor Antagonists Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst